このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Zhongzhi Pharmaceutical Holdings 将来の成長

Future 基準チェック /06

現在、 Zhongzhi Pharmaceutical Holdingsの成長と収益を予測するのに十分なアナリストの調査がありません。

主要情報

n/a

収益成長率

n/a

EPS成長率

Pharmaceuticals 収益成長	10.7%
収益成長率	n/a
将来の株主資本利益率	n/a
アナリストカバレッジ	None
最終更新日	n/a

今後の成長に関する最新情報

Recent updates

Calculating The Intrinsic Value Of Zhongzhi Pharmaceutical Holdings Limited (HKG:3737)

Jun 19

Most Shareholders Will Probably Agree With Zhongzhi Pharmaceutical Holdings Limited's (HKG:3737) CEO Compensation

May 10

Zhongzhi Pharmaceutical Holdings (HKG:3737) Is Reducing Its Dividend To CN¥0.03

May 05

Zhongzhi Pharmaceutical Holdings (HKG:3737) Is Reducing Its Dividend To CN¥0.03

Apr 21

Zhongzhi Pharmaceutical Holdings Limited's (HKG:3737) Prospects Need A Boost To Lift Shares

Feb 01

These 4 Measures Indicate That Zhongzhi Pharmaceutical Holdings (HKG:3737) Is Using Debt Reasonably Well

May 24

Is Zhongzhi Pharmaceutical Holdings (HKG:3737) A Risky Investment?

Aug 26

Zhongzhi Pharmaceutical Holdings (HKG:3737) Has A Pretty Healthy Balance Sheet

Apr 28

These 4 Measures Indicate That Zhongzhi Pharmaceutical Holdings (HKG:3737) Is Using Debt Reasonably Well

Jun 11

Investors Met With Slowing Returns on Capital At Zhongzhi Pharmaceutical Holdings (HKG:3737)

May 06

Zhongzhi Pharmaceutical Holdings (HKG:3737) Strong Profits May Be Masking Some Underlying Issues

Apr 21

Do Zhongzhi Pharmaceutical Holdings's (HKG:3737) Earnings Warrant Your Attention?

Mar 29

The Zhongzhi Pharmaceutical Holdings (HKG:3737) Share Price Has Gained 50% And Shareholders Are Hoping For More

Mar 05

Is Zhongzhi Pharmaceutical Holdings Limited's(HKG:3737) Recent Stock Performance Tethered To Its Strong Fundamentals?

Feb 15

What Is The Ownership Structure Like For Zhongzhi Pharmaceutical Holdings Limited (HKG:3737)?

Jan 14

Would Zhongzhi Pharmaceutical Holdings Limited (HKG:3737) Be Valuable To Income Investors?

Dec 27

If You Like EPS Growth Then Check Out Zhongzhi Pharmaceutical Holdings (HKG:3737) Before It's Too Late

Dec 14

Did You Miss Zhongzhi Pharmaceutical Holdings' (HKG:3737) 31% Share Price Gain?

Nov 30

Is Zhongzhi Pharmaceutical Holdings Limited's(HKG:3737) Recent Stock Performance Tethered To Its Strong Fundamentals?

Nov 17

このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Zhongzhi Pharmaceutical Holdings は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。

シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。

業績と収益の成長予測

SEHK:3737 - アナリストの将来予測と過去の財務データ ( )CNY Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2023	2,050	163	-70	102	N/A
9/30/2023	2,062	164	18	168	N/A
6/30/2023	2,074	164	106	234	N/A
3/31/2023	1,950	135	151	259	N/A
12/31/2022	1,826	106	195	285	N/A
9/30/2022	1,766	84	147	263	N/A
6/30/2022	1,706	63	98	242	N/A
3/31/2022	1,726	57	44	210	N/A
12/31/2021	1,747	52	-9	178	N/A
9/30/2021	1,750	93	-46	132	N/A
6/30/2021	1,753	133	-83	86	N/A
3/31/2021	1,678	136	-54	90	N/A
12/31/2020	1,604	139	-25	93	N/A
9/30/2020	1,524	133	29	120	N/A
6/30/2020	1,444	128	82	147	N/A
3/31/2020	1,393	121	92	157	N/A
12/31/2019	1,342	115	102	168	N/A
9/30/2019	1,282	106	88	160	N/A
6/30/2019	1,221	97	75	152	N/A
3/31/2019	1,182	91	39	116	N/A
12/31/2018	1,142	85	4	80	N/A
9/30/2018	1,106	82	-15	55	N/A
6/30/2018	1,070	79	-35	29	N/A
3/31/2018	1,007	74	-19	40	N/A
12/31/2017	945	70	-2	51	N/A
9/30/2017	874	65	N/A	52	N/A
6/30/2017	803	60	N/A	53	N/A
3/31/2017	767	57	N/A	51	N/A
12/31/2016	730	54	N/A	49	N/A
9/30/2016	715	52	N/A	41	N/A
6/30/2016	700	50	N/A	34	N/A
3/31/2016	694	65	N/A	45	N/A
12/31/2015	688	81	N/A	56	N/A
9/30/2015	671	91	N/A	80	N/A
6/30/2015	655	101	N/A	104	N/A
3/31/2015	625	94	N/A	113	N/A
12/31/2014	596	87	N/A	122	N/A
12/31/2013	483	38	N/A	45	N/A

アナリストによる今後の成長予測

収入対貯蓄率: 3737の予測収益成長が貯蓄率 ( 2.2% ) を上回っているかどうかを判断するにはデータが不十分です。

収益対市場: 3737の収益がHong Kong市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です

高成長収益: 3737の収益が今後 3 年間で大幅に増加すると予想されるかどうかを判断するにはデータが不十分です。

収益対市場: 3737の収益がHong Kong市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。

高い収益成長: 3737の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: 3737の自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Zhongzhi Pharmaceutical Holdings 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Zhongzhi Pharmaceutical Holdings Limited Provides Consolidated Earnings Guidance for the Year Ended 31 December 2023

Zhongzhi Pharmaceutical Holdings Limited Provides Earnings Guidance for the Six Months Ended June 30, 2023

Zhongzhi Pharmaceutical Holdings Limited Provides Unaudited Consolidated Earnings Guidance for the Year Ended December 31, 2022

Zhongzhi Pharmaceutical Holdings Limited Provides Consolidated Earnings Guidance for the Year Ended December 31, 2021

Recent updates

Calculating The Intrinsic Value Of Zhongzhi Pharmaceutical Holdings Limited (HKG:3737)

Now 20% undervalued after recent price drop

Zhongzhi Pharmaceutical Holdings Limited Approves the Declaration and Payment of Final Dividend

Upcoming dividend of HK$0.03 per share

Most Shareholders Will Probably Agree With Zhongzhi Pharmaceutical Holdings Limited's (HKG:3737) CEO Compensation

Zhongzhi Pharmaceutical Holdings (HKG:3737) Is Reducing Its Dividend To CN¥0.03

Zhongzhi Pharmaceutical Holdings (HKG:3737) Is Reducing Its Dividend To CN¥0.03

Zhongzhi Pharmaceutical Holdings Limited, Annual General Meeting, May 17, 2024

Chairman recently bought HK$4.0m worth of stock

Full year 2023 earnings released: EPS: CN¥0.19 (vs CN¥0.13 in FY 2022)

Final dividend of HK$0.03 announced

Zhongzhi Pharmaceutical Holdings Limited to Report Fiscal Year 2023 Results on Mar 22, 2024

Zhongzhi Pharmaceutical Holdings Limited's (HKG:3737) Prospects Need A Boost To Lift Shares

Zhongzhi Pharmaceutical Holdings Limited Provides Consolidated Earnings Guidance for the Year Ended 31 December 2023

Chairman recently bought HK$1.4m worth of stock

Zhongzhi Pharmaceutical Holdings Limited Approves Interim Dividend

Upcoming dividend of HK$0.06 per share at 8.8% yield

Chairman recently bought HK$467k worth of stock

First half 2023 earnings released: EPS: CN¥0.16 (vs CN¥0.091 in 1H 2022)

Chairman recently bought HK$135k worth of stock

Chairman recently bought HK$955k worth of stock

First half 2023 earnings released: EPS: CN¥0.16 (vs CN¥0.091 in 1H 2022)

Zhongzhi Pharmaceutical Holdings Limited Proposes Interim Dividend for the Six Months Ended 30 June 2023, Payable on 2 November 2023

Investor sentiment improves as stock rises 15%

Zhongzhi Pharmaceutical Holdings Limited to Report First Half, 2023 Results on Aug 23, 2023

Zhongzhi Pharmaceutical Holdings Limited Provides Earnings Guidance for the Six Months Ended June 30, 2023

These 4 Measures Indicate That Zhongzhi Pharmaceutical Holdings (HKG:3737) Is Using Debt Reasonably Well

Zhongzhi Pharmaceutical Holdings Limited Approves the Declaration and Payment of Special Dividend

Upcoming dividend of HK$0.09 per share at 5.4% yield

Full year 2022 earnings released: EPS: CN¥0.13 (vs CN¥0.062 in FY 2021)

Zhongzhi Pharmaceutical Holdings Limited Provides Unaudited Consolidated Earnings Guidance for the Year Ended December 31, 2022

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Less than half of directors are independent

Deputy GM & Executive Director recently bought HK$229k worth of stock

Is Zhongzhi Pharmaceutical Holdings (HKG:3737) A Risky Investment?

First half 2022 earnings released: EPS: CN¥0.091 (vs CN¥0.081 in 1H 2021)

Zhongzhi Pharmaceutical Holdings Limited to Report First Half, 2022 Results on Aug 25, 2022

Chairman recently bought HK$177k worth of stock

Zhongzhi Pharmaceutical Holdings (HKG:3737) Has A Pretty Healthy Balance Sheet

Chairman recently bought HK$448k worth of stock

Less than half of directors are independent

Zhongzhi Pharmaceutical Holdings Limited, Annual General Meeting, May 20, 2022

Investor sentiment improved over the past week

Chairman recently bought HK$925k worth of stock

Investor sentiment improved over the past week

Chairman recently bought HK$1.8m worth of stock

Zhongzhi Pharmaceutical Holdings Limited Provides Consolidated Earnings Guidance for the Year Ended December 31, 2021

Investor sentiment improved over the past week

First half 2021 earnings released: EPS CN¥0.081 (vs CN¥0.086 in 1H 2020)

These 4 Measures Indicate That Zhongzhi Pharmaceutical Holdings (HKG:3737) Is Using Debt Reasonably Well

Investors Met With Slowing Returns on Capital At Zhongzhi Pharmaceutical Holdings (HKG:3737)

Zhongzhi Pharmaceutical Holdings (HKG:3737) Strong Profits May Be Masking Some Underlying Issues

Full year 2020 earnings released: EPS CN¥0.17 (vs CN¥0.14 in FY 2019)

Do Zhongzhi Pharmaceutical Holdings's (HKG:3737) Earnings Warrant Your Attention?

Full year 2020 earnings released: EPS CN¥0.17 (vs CN¥0.14 in FY 2019)

Investor sentiment deteriorated over the past week

Zhongzhi Pharmaceutical Holdings Limited to Report Fiscal Year 2020 Results on Mar 24, 2021

The Zhongzhi Pharmaceutical Holdings (HKG:3737) Share Price Has Gained 50% And Shareholders Are Hoping For More

Is Zhongzhi Pharmaceutical Holdings Limited's(HKG:3737) Recent Stock Performance Tethered To Its Strong Fundamentals?

New 90-day high: HK$1.76

What Is The Ownership Structure Like For Zhongzhi Pharmaceutical Holdings Limited (HKG:3737)?

Would Zhongzhi Pharmaceutical Holdings Limited (HKG:3737) Be Valuable To Income Investors?

If You Like EPS Growth Then Check Out Zhongzhi Pharmaceutical Holdings (HKG:3737) Before It's Too Late

Did You Miss Zhongzhi Pharmaceutical Holdings' (HKG:3737) 31% Share Price Gain?

Is Zhongzhi Pharmaceutical Holdings Limited's(HKG:3737) Recent Stock Performance Tethered To Its Strong Fundamentals?

Upcoming Dividend of HK$0.051 Per Share

First half earnings released

First half earnings released

New 90-day high - HK$1.90

Zhongzhi Pharmaceutical Holdings Limited to Report First Half, 2020 Results on Aug 26, 2020